Conexiant
Login
  • The Analytical Scientist
  • The Cannabis Scientist
  • The Medicine Maker
  • The Ophthalmologist
  • The Pathologist
  • The Traditional Scientist
The Medicine Maker
  • Explore

    Explore

    • Latest
    • Features
    • Interviews
    • Business & Trends
    • Technology & Manufacturing
    • Product Profiles
    • White Papers

    Featured Topics

    • Biopharma
    • Small Molecules
    • Cell & Gene
    • Future of Pharma

    Issues

    • Latest Issue
    • Archive
    • Cell and Gene Therapy Supplement
  • Topics

    Topics

    • Drug Discovery
    • Development & Clinical
    • Formulation
    • Drug Delivery
    • Bioprocessing
    • Small Molecules
    • Cell and Gene
    • Facilities & Equipment
    • Outsourcing
    • Packaging
    • Supply Chain
    • Regulation & Standards
  • News & Blogs

    News & Blogs

    • Industry News
    • Research News
    • Blogs
  • Events
    • Live Events
    • Webinars
  • Community & Awards

    Community & Awards

    • Power List
    • Sitting Down With
    • Innovation Awards
    • Company of the Year Awards
    • Authors & Contributors
  • Multimedia
    • Video
    • Podcasts
    • eBooks
Subscribe
Subscribe
The Medicine Maker / Authors / Markus Hartmann

Markus Hartmann

“Following the evolution of research and development from a bird’s eye perspective is a highly interesting and awarding endeavor,” says Markus Hartmann. “After completing my PhD in medicinal chemistry investigating new anti-tumor agents in 1996, I was interested to learn how the molecules are then tested in humans and, later on, how all the data compiled on a new agent are compiled for marketing authorization purposes.” Having taken over roles as medical advisor in pharmaceutical corporations or as regulatory consultant serving scientific networks, Markus admits that combining scientific rigor, medical and clinical expertise, and regulatory and legal knowledge under one hat is a great challenge, but a continuously stimulating experience for his present and future work. His specific interest lies in the regulatory and legal questions that surround clinical research for drugs, devices and diagnostics.

  • Contributions

Clinical Compromise for Europe

September 22, 2014

After years of intense criticism, the European Parliament has adopted a new regulation for clinical trials that will replace the current EU Clinical Trials Directive by mid-2016. But is it enough to reverse a decade of decline in European clinical research?

1 min read

Clinical Compromise for Europe

Newsletters

Receive the latest analytical science news, personalities, education, and career development – weekly to your inbox.

Newsletter Signup Image

False

Advertisement

Recommended

False

The Medicine Maker
Subscribe

About

  • About Us
  • Work at Conexiant Europe
  • Terms and Conditions
  • Privacy Policy
  • Advertise With Us
  • Contact Us

Copyright © 2025 Texere Publishing Limited (trading as Conexiant), with registered number 08113419 whose registered office is at Booths No. 1, Booths Park, Chelford Road, Knutsford, England, WA16 8GS.